

**Clinical Expert Summary
Lopinavir/ritonavir (Kaletra®) 80 mg/20 mg oral solution**

Lopinavir/ritonavir (Kaletra®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.

1. Existing guidelines

Reference was made to British HIV Association (BHIVA), Children's HIV Association (CHIVA) and local guidelines.

2. Disease prevalence/incidence

It was noted that there are very few children in Wales with HIV. The number of patients under two years of age eligible for this medicine is therefore expected to be very small.

3. Current treatment options

It was noted that a wide range of other antiretrovirals (not all of which are licensed for use in this group of patients) are used on an individual patient basis, guided by clinicians with expertise in this area.

4. Unmet needs

HIV is a chronic condition that is controllable with medication. All currently available medicines have side effects. There is not one treatment option that is suitable for all patients, therefore, access to a variety of medicines is important to allow clinicians to construct a treatment regime that is suitable for the majority of patients.

It should be noted that one expert involved in compiling this response declared a personal specific interest in relation to lopinavir/ritonavir for the indication under consideration.